SK bioscience acquired an improved MSCI ESG rating from B->BBB in one year

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, announced that the company has received an upgrade MSCI(Morgan Stanley Capital International) ESG(Environmental, Social, Governance) rating from B to BBB in one year.

According to the rating report, SK bioscience was recognized for its human resources development in the social(S) category and transparency of the board of directors and accounting risk management through systematic audits and information disclosure in the governance(G) category.

SK bioscience recently recruited executives one after another to strengthen sustainable growth momentum and conducted an annual culture survey for employees to pursue the corporate value, “Happy Business Management.”

SK bioscience also separated the chairman of the board from the CEO and included financial experts in the audit committee, improving the governance system.

Separately, SK bioscience obtained the highest level among biotechnology industry in South Korea, grade A or higher in all categories of the ´2022 Listed Companies ESG Evaluation and Rating Announcement´ conducted by the Korea Institute of Corporate Governance and Sustainability (KCGS)in November 2022.

Since 1999, MSCI has evaluated, listed companies around the world under 10 themes with 35 key issues in environment, society, and governance categories and announced the rating results every year.

Jaeyong Ahn, CEO of SK bioscience said, “ESG management has become a critical asset for global companies. We will always pursue the happiness of our stakeholders and establish the advanced management environment centered on our core mission.”